Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2011
11/01/2011CA2452056C Compositions of bioactive material particles dispersed in a continuous solid encapsulating material
11/01/2011CA2443089C Antifungal suspension of micronized posaconazole
11/01/2011CA2439269C Pharmaceutical salts of 1-phenyl-3-dimethylaminopropane compounds
11/01/2011CA2434526C Methods of administering epothilone analogs for the treatment of cancer
11/01/2011CA2431241C Amphiphilic polymers for medical applications
11/01/2011CA2402247C Biodegradable immunomodulatory formulations and methods for use thereof
11/01/2011CA2395459C Use of quinoline and quinolizinone derivatives as chemotherapeutic agents
11/01/2011CA2275890C Stable liquid interferon formulations
10/2011
10/27/2011WO2011133980A1 Therapeutic formulation for reduced drug side effects
10/27/2011WO2011133925A2 Targeted and light-activated cytosolic drug delivery
10/27/2011WO2011133911A1 An effervescent carrier, a method of changing the flavor of milk, and an effervescent tablet for changing the flavor of milk
10/27/2011WO2011133867A2 Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration
10/27/2011WO2011133855A1 Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy
10/27/2011WO2011133841A2 Intravenous omega-3 fatty acid compositions & method of use
10/27/2011WO2011133685A2 Nanoparticle targeting to ischemia for imaging and therapy
10/27/2011WO2011133675A1 Gabapentin enacarbil compositions
10/27/2011WO2011133635A2 Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
10/27/2011WO2011133617A1 Nano-hybrid delivery system for sequential utilization of passive and active targeting
10/27/2011WO2011133611A1 Thiazolidinedione analogues
10/27/2011WO2011133566A2 Repairing bruch's membrane with hydrogels
10/27/2011WO2011133475A2 Compositions and method for the treatment of multiple myeloma
10/27/2011WO2011133463A2 Antimicrobial compositions comprising organic acid esters and methods for reducing virus and bacterial populations using such compositions
10/27/2011WO2011133370A1 Shelf stable pharmaceutical depot
10/27/2011WO2011133064A1 Method for producing an agent for eliminating skin defects and for treating wounds in the form of a gel based on water-soluble plant-derived polysaccharides
10/27/2011WO2011132966A2 Transdermal absorption preparation
10/27/2011WO2011132826A1 Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases
10/27/2011WO2011132718A1 Composition containing reduced coenzyme q10, and manufacturing and stabilising methods therefor
10/27/2011WO2011132713A1 Lipid membrane structure with nuclear transferability
10/27/2011WO2011132167A1 Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
10/27/2011WO2011132157A1 Oral sustained release formulation of huperzine a
10/27/2011WO2011131947A2 A process for particle processing of active pharmaceutical ingredients
10/27/2011WO2011131765A2 Artificial tear emulsion
10/27/2011WO2011131663A1 "process for providing particles with reduced electrostatic charges"
10/27/2011WO2011131644A1 Capsule comprising active ingredient
10/27/2011WO2011131636A1 Combined treatment of cancer with benzo[e]pyridoindoles and dna-damaging agents
10/27/2011WO2011131445A1 Active ingredient combinations of magnolia bark extract and polyethoxylated compounds (peg-40 stearates)
10/27/2011WO2011131441A1 Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate)
10/27/2011WO2011131439A1 Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates
10/27/2011WO2011131370A1 Melt-granulated fingolimod
10/27/2011WO2011131369A1 Fingolimod in the form of a solid solution
10/27/2011WO2011131348A1 Aliskiren in form of a solid dispersion
10/27/2011WO2011131347A1 Pramipexole-containing matrix tablet
10/27/2011WO2011131203A2 A solid pharmaceutical composition for neutralizing stomach acid
10/27/2011WO2011130892A1 Traditional chinese medicinal composition for treating influenza and preparation method and use thereof
10/27/2011WO2011130834A1 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
10/27/2011WO2011101865A3 Stable pharmaceutical compositions of clopidogrel for parenteral delivery
10/27/2011WO2011101456A3 Stabilized phenylcarbamate derivative in solid state
10/27/2011WO2011084451A3 Methods and compositions for liquidation of tumors
10/27/2011WO2011075799A3 Oral antidepressant formulation
10/27/2011WO2011072103A3 Glycerine based jelly compositions
10/27/2011WO2011069082A3 Red blood cell-mimetic particles and methods for making and use thereof
10/27/2011WO2011062420A3 Nanoparticles for tumor-targeting and processes for the preparation thereof
10/27/2011WO2011061641A3 Cooling substrates with hydrophilic containment layer and method of making
10/27/2011WO2011060944A8 Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
10/27/2011WO2011060390A3 Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
10/27/2011WO2011059262A3 Uses of apoptotic cell-targeting peptides, label substances and liposomes containing a therapeutic agent for preventing, treating or therapeutically diagnosing apoptosis-related diseases
10/27/2011WO2011056773A3 Inhibiting neurotransmitter reuptake
10/27/2011WO2011056653A3 Clonidine formulations having antimicrobial properties
10/27/2011WO2011039510A3 Conjugates targeting the cd163 receptor
10/27/2011WO2010143971A3 Lipophilic drug carrier
10/27/2011WO2010130396A3 Preparation of acetyl salicylic acid/glutamic acid complex for oral administration
10/27/2011WO2010121600A3 Particulate pharmaceutical composition having an opioid and an opioid antagonist
10/27/2011WO2010119365A3 A medicinal cream made using clotrimazole and chitosan and a process to make the same
10/27/2011WO2010103374A8 Oily suspension containing probiotic bacteria for paediatric uses
10/27/2011WO2010081443A3 Dosage forms of tyrosine kinase inhibitors
10/27/2011WO2009117401A3 Compositions for site-specific delivery of imatinib and methods of use
10/27/2011US20110263632 Solid dispersions comprising tacrolimus
10/27/2011US20110263587 Reversibly heat-gelable aqueous composition
10/27/2011US20110263568 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
10/27/2011US20110263543 Anti inflammatory compounds
10/27/2011US20110263492 Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension of dispersion media
10/27/2011US20110262549 Lipid pellets with enhanced taste-masking
10/27/2011US20110262548 Novel prostaglandin e1 derivative and nanoparticle having the same encapsulated therein
10/27/2011US20110262547 Process for preparing carrier particles for dry powders for inhalation
10/27/2011US20110262546 Gold nanoparticles coated with polyelectrolytes and albumin
10/27/2011US20110262545 Octreotide depot formulation with constantly high exposure levels
10/27/2011US20110262544 Ophthalmic administration of a composition including brimonidine as a mist
10/27/2011US20110262543 Process for providing particles with reduced electrostatic charges
10/27/2011US20110262542 Controlled Delivery of Tetracycline Compounds and Tetracycline Derivatives
10/27/2011US20110262541 Foam-formed collagen strand
10/27/2011US20110262540 Solid Pharmaceutical Composition Comprising Exemestane
10/27/2011US20110262539 Pharmaceutical compositions
10/27/2011US20110262538 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
10/27/2011US20110262537 Extended release dosage form of ropinirole
10/27/2011US20110262536 Method to authenticate genuine tablets manufactured by compressing powder
10/27/2011US20110262535 Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof
10/27/2011US20110262534 polysaccharide capsule enclosing a fatty acid oil-containing emulsion
10/27/2011US20110262533 Pharmaceutical formulation for use in hiv therapy
10/27/2011US20110262532 Controlled Release Hydrocodone Formulations
10/27/2011US20110262531 Nanoparticulate system, process for the preparation of the same, use of the same, photoprotective composition, process for the preparation of the same, method of prevention of diseases of the skin
10/27/2011US20110262530 Sustained release of apo a-i mimetic peptides and methods of treatment
10/27/2011US20110262529 Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof
10/27/2011US20110262528 Pharmaceutical composition for the prevention and treatment of bone tissue resorption of various etiology
10/27/2011US20110262527 Cationic lipids and methods of use
10/27/2011US20110262526 Method of inducing an anti-viral immune response
10/27/2011US20110262525 Methods of treatment
10/27/2011US20110262524 Liposomes with improved drug retention for treatment of cancer
10/27/2011US20110262523 medical adhesive tape and medical articles made of the same
10/27/2011US20110262522 Transmucosal delivery devices with enhanced uptake
10/27/2011US20110262521 Medical device including bacterial cellulose reinforced by resorbable or non resorbable reinforcing materials
1 ... 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 ... 2991